Application of organoids and patient-derived xenograft models in cancer research
CSTR:
Author:
Affiliation:

(1. Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. 2. NHC KeyLaboratory of Human Disease Comparative Medicine, Institute of Laboratory Animal Sciences,CAMS & PUMC, Beijing 100021. 3. Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Beijing 100021)

Clc Number:

R-33

  • Article
  • | |
  • Metrics
  • | | |
  • Cited by
  • | |
  • Comments
    Abstract:

    Patient-derived organoids (PDOs) and patient-derived xenografts (PDXs) are new models for cancerresearch. They can accurately simulate the physiological structures and characteristics of in situ tissues, help to formulateappropriate medication regimens for patients, and achieve individualized treatment. Thus, they are necessary for the rapidtransformation of basic scientific research to clinical applications. In addition, PDO and PDX models can be used to carryout basic research on tumor clonal evolution and tumor pathogenesis. This review focuses on the application of PDO and PDX models in cancer preclinical and basic research.

    Reference
    Related
    Cited by
Get Citation
Share
Article Metrics
  • Abstract:3158
  • PDF: 4328
  • HTML: 0
  • Cited by: 0
History
  • Received:September 08,2018
  • Online: April 10,2019
Article QR Code